Physician profile
Mark William Pickhardt
NPI 1295122315
$2,985.68
in general payments reported to CMS, 2019-2025
36 companies · $361 in 2025
The $361 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,179 · 2020: $143 · 2021: $224 · 2022: $459 · 2023: $305 · 2024: $314 · 2025: $361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $981.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $980.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,249.14 | 2019-2025 | Axonics |
| Procept Biorobotics Corporation | $205.06 | 2021-2024 | Aquabeam System |
| Merck Sharp & Dohme LLC | $162.24 | 2020-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Regeneron Healthcare Solutions, INC. | $122.97 | 2021-2024 | Libtayo |
| Axonics, INC. | $121.87 | 2022 | |
| Accord Healthcare, INC. | $89.25 | 2023-2024 | |
| Janssen Biotech, INC. | $86.17 | 2022-2025 | Darzalex, Talvey, Tecvayli |
| Palette Life Sciences, INC. | $77.50 | 2023 | |
| Coloplast Corp | $73.10 | 2024-2025 | |
| Medtronic, INC. | $64.35 | 2022-2025 | Interstim |
| Myovant Sciences INC. | $62.23 | 2022 | |
| Sumitomo Pharma America, INC. | $53.62 | 2023-2025 | Orgovyx |
| Novartis Pharmaceuticals Corporation | $50.78 | 2025 | |
| Aveo Pharmaceuticals, INC. | $48.81 | 2024-2025 | |
| Daiichi Sankyo INC. | $41.62 | 2022-2025 | Enhertu |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $40.92 | 2021-2023 | Provenge |
| Acceleron Pharma, INC. | $40.69 | 2020-2021 | |
| Ferring Pharmaceuticals INC. | $36.31 | 2025 | Adstiladrin |
| Astellas Pharma US INC | $34.56 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $34.20 | 2020-2021 | |
| Verity Pharmaceuticals INC. | $29.10 | 2023 | Trelstar |
| Pharmaand Gmbh | $27.42 | 2025 | Rubraca |
| Tolmar, INC. | $26.46 | 2025 | Eligard, Rubraca |
| Incyte Corporation | $24.63 | 2020 | |
| Blue Earth Diagnostics | $24.57 | 2020-2021 | |
| Urogen Pharma, INC. | $20.91 | 2025 | |
| Teleflex LLC | $18.81 | 2023 | Quikclot |
| Pfizer INC. | $15.25 | 2025 | |
| Genmab U.S., INC. | $15.08 | 2023 | Epkinly |
| Myriad Genetic Laboratories, INC. | $13.96 | 2022 | |
| Davol INC. | $13.08 | 2020 | |
| Beigene USA, INC. | $13.07 | 2024 | Brukinsa |
| Iovance Biotherapeutics, INC. | $13.04 | 2025 | Amtagvi |
| Blueprint Medicines Corporation | $12.35 | 2021 | |
| Amgen INC. | $11.52 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Pickhardt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.